Table 1.
Characteristics of kidney transplant recipients included in the COVID-19 registry.
| All | Recovered | Deceased | p | |
|---|---|---|---|---|
| n = 165 | n = 137 | n = 28 | ||
| Males | 99 (60.0%) | 82 (59.9%) | 17 (60.7%) | .449 |
| Age (years) | ||||
| Mean (SD) | 49 (14) | 46 (14) | 60 (11) | .000 |
| Median (IQR) | 48 (38–60) | 44 (36–56) | 59 (54–68) | |
| Range | 12–85 | 12–76 | 42–85 | |
| >60 | 40 (24.2%) | 27 (19.7%) | 13 (46.4%) | .003 |
| BMI (kg/cm2) | ||||
| Mean (SD) | 25.5 (3.8) | 25.3 (3.8) | 26.4 (4.0) | .169 |
| Range | 18–45 | 18–45 | 18–36 | |
| Months since transplant | ||||
| Mean (SD) | 6.4 (5.7) | 6.7 (5.6) | 4.8 (5.6) | .103 |
| Range | 0–34.5 | 0.1–34.5 | 0–19.8 | |
| Less than 6 months | 14 (8.5%) | 9 (6.6%) | 5 (17.9%) | .056 |
| Hypertension | 115 (69.7%) | 93 (67.9%) | 22 (78.6%) | .185 |
| Diabetes | 44 (26.7%) | 28 (20.4%) | 16 (57.1%) | .001 |
| BMI > 30 kg/m2 | 14 (8.5%) | 11 (8.0%) | 3 (10.7%) | .463 |
| Immunosuppression | ||||
| CNI | 106 (64.2%) | 83 (60.6%) | 23 (82.1%) | .025 |
| Tacrolimus | 99 (60.0%) | 78 (56.9%) | 21 (75%) | .05 |
| mTor inhibitors | 25 (15.2%) | 23 (16.8%) | 2 (7.1%) | .159 |
| Belatacept | 35 (21.2%) | 31 (22.6%) | 4 (14.3%) | .233 |
| MPA | 152 (92.1%) | 127 (92.7%) | 25 (89.3%) | .41 |
| Azathioprine | 7 (4.2%) | 5 (3.6%) | 2 (7.1%) | .374 |
| Steroids | 130 (78.8%) | 104 (75.9%) | 26 (92.9%) | .041 |
| Presenting symptoms | ||||
| Fever | 98 (59.4%) | 80 (58.4%) | 18 (64.3%) | .357 |
| Cough | 91 (55.2%) | 74 (54.0%) | 17 (60.7%) | .329 |
| Dyspnea | 64 (38.8%) | 48 (35.0%) | 16 (57.1%) | .024 |
| Clinical variables | ||||
| Hypoxemia | 63 (38.2%) | 37 (27.0%) | 26 (92.9%) | <.001 |
| Pulmonary infiltrates | 87 (52.7%) | 61 (44.5%) | 26 (92.9%) | <.001 |
| Hospitalization | 82 (49.7%) | 55 (40.1%) | 27 (96.4%) | <.001 |
| Mechanical ventilation | 36 (21.8%) | 12 (8.8%) | 24 (85.7%) | <.001 |
| Hemodialysis | 15 (9.1%) | 3 (2.2%) | 12 (42.9%) | <.001 |
| Treatment | ||||
| Hydroxychloroquine | 3 (1.8%) | 3 (2.2%) | 0 (0.0%) | .285 |
| Lopinavir/ritonavir | 1 (0.6%) | 1 (0.7%) | 0 (0.0%) | .321 |
| Ivermectin | 31 (18.8%) | 16 (11.7%) | 15 (53.6%) | <.001 |
| Dexamethasone | 53 (32.1%) | 28 (20.4%) | 25 (89.3%) | <.001 |
| Antibiotics | 66 (40.0%) | 41 (29.9%) | 25 (89.3%) | <.001 |
BMI, body mass index; CNI, calcineurin inhibitors; IQR, inter-quartile range; MPA, mycophenolic acid; SD, standard deviation.